Evaluation of Sleeping Profile in Schizophrenia Patients Treated with Paliperidone-Extended Release: Result From an Open Labeled Perspective Study in South East Asia (Perfect Study)

Abstract

Objective

To evaluate the impact of treatment with paliperidone extended release for 6 months on sleeping profile in schizophrenia patients.

Methods

A total of 984 patients meeting the DSM-IV criteria for schizophrenia who switched their antipsychotics to be paliperidone ER were recruited from 61 sites in five countries in Southeast Asia. We assessed patients in terms of demographic profile, sleep quality and daytime drowsiness as visual analog scale.

Results

Patients in our studies received paliperidone ER treatment for 6 months. About 70% completed the treatment. Sleep quality and also daytime drowsiness were significantly increased in patients compared with their baseline. The predictive factors that have effect on sleep profile improvement were completion of the study and baseline PANSS score.

Conclusion

Patients receiving paliperidone ER were found to have improvement in sleep quality and also improvement in daytime drowsiness, especially in patients within completion group and the higher baseline PANSS score.

Disclosure of interest

The author has not supplied his/her declaration of competing interest.